Barry Bunin on Clubhouse

Bio

Barry A. Bunin, Ph.D. is the CEO of Collaborative Drug Discovery (www.collaborativedrug.com) creator of CDD Vault, the first hosted drug discovery informatics platform.

Prior to CDD, he was an Entrepreneur in Residence with Eli Lilly & Co. Dr. Bunin is on a patent for Kyprolis™ (Carfilzomib for Injection) — a selective proteasome inhibitor that received accelerated FDA approval for the treatment of patients with multiple myeloma that was widely viewed as the centerpiece of Amgen’s $10.4 Billion acquisition of Onyx Pharmaceuticals.

Dr. Bunin was the founding CEO, President, & CSO of Libraria (now Eidogen-Sertanty). At Libraria, he led a team that integrated exhaustive reaction capture (synthetic chemistry) with gene-family wide SAR capture (medicinal chemistry). On the scientific side, he co-authored “Chemoinformatics: Theory, Practice, and Products” (Springer-Verlag), a text that overviews modern chemoinformatics technologies, and “The Combinatorial Index” (Academic Press), a widely used text on high-throughput chemical synthesis.

In the lab, Dr. Bunin did medicinal synthetic chemistry developing patented new chemotypes for protease inhibition at Axys Pharmaceuticals (now Celera) and RGD mimics to inhibit GP-IIbIIIa at Genentech. Dr. Bunin received his B.A. from Columbia University and his Chemistry Ph.D. from UC Berkeley, where he synthesized and tested the initial 1,4-benzodiazepine libraries with Professor Jonathan Ellman.

Dr. Bunin has overseen $50 million in business transactions over the last two decades.

House of Prelon is pretty funny.

#prelon

After CDD Vault (www.collaborativedrug.com), CDD recently launched “The Pharmaceutical Knowledgebase” for those curious to 👀 deeper into the Disease - Drug - Company trilogy:

www.PharmaKB.com